Company: ARMP
Filing Date: 2025-12-01
Form Type: 424B5
Source: 0001104659-25-117382
Chunk: 47

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-12-01
Form: 424B5
Chunk 47
---
 our common stock or preferred stock.

The debt securities will be
issued under an indenture, as supplemented by a resolution of our board of directors, an officer’s certificate or a supplemental
indenture, between us and a trustee. We have summarized the general features of the debt securities to be governed by the indenture. The
indenture has been filed as an exhibit to the registration statement of which this prospectus forms a part. We encourage you to read the
indenture. Instructions on how you can get copies of this document are provided under the heading “Where You Can Find More Information.”

Units

We may issue units comprised
of one or more of the other classes of securities issued by us as described in this prospectus in any combination. Each unit will be issued
so that the holder of the unit is also the holder of each security included in the unit.

<div align='center'>10

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>

This prospectus and the documents
incorporated by reference herein contain forward-looking statements. The forward-looking statements are contained principally in the sections
entitled “Prospectus Summary” and “Risk Factors” in this prospectus or the documents incorporated herein by reference.
These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and
other factors which may cause our actual results, performance or events to be materially different from any future results, performance
or events expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements
regarding:

| · | our estimates regarding anticipated operating                
 losses, capital requirements and needs for additional funds; |

| · | our ability to raise additional capital when 
 needed and to continue as a going concern;   |

| · | our ability to manufacture, or otherwise secure                                                                   
 the manufacture of, sufficient amounts of our product candidates for our preclinical studies and clinical trials; |

| · | our clinical development plans, including planned 
 clinical trials;                                  |

| · | our research and development plans; |

| · | our ability to select combinations of phages 
 to formulate our product candidates;         |

| · | our development of bacteriophage-based therapies; |

| · | the potential use of bacteriophages to treat 
 bacterial infections;                        |

| · | the potential future of antibiotic resistance; |

| · | the ability for bacteriophage therapies to disrupt           
 and destroy biofilms and restore sensitivity to antibiotics; |